Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 245

1.

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.

Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M.

J Pharm Pharmacol. 2014 Jul;66(7):975-87. doi: 10.1111/jphp.12223. Epub 2014 Feb 17.

PMID:
24533859
2.

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.

Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M.

Eur J Pharmacol. 2013 Sep 5;715(1-3):246-55. doi: 10.1016/j.ejphar.2013.05.014. Epub 2013 May 23.

PMID:
23707905
3.

Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.

Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M.

J Pharmacol Sci. 2012;120(1):36-44. Epub 2012 Aug 23.

4.

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.

Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Apr;385(4):423-36. doi: 10.1007/s00210-011-0713-z. Epub 2011 Dec 3.

PMID:
22139434
5.

Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.

Veltkamp SA, Kadokura T, Krauwinkel WJ, Smulders RA.

Clin Drug Investig. 2011 Dec 1;31(12):839-51. doi: 10.2165/11594330-000000000-00000.

PMID:
21877761
6.

Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.

Hayashizaki-Someya Y, Kurosaki E, Takasu T, Mitori H, Yamazaki S, Koide K, Takakura S.

Eur J Pharmacol. 2015 May 5;754:19-24. doi: 10.1016/j.ejphar.2015.02.009. Epub 2015 Feb 19.

PMID:
25701721
7.

Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats.

Takakura S, Toyoshi T, Hayashizaki Y, Takasu T.

Life Sci. 2016 Feb 15;147:125-31. doi: 10.1016/j.lfs.2016.01.042. Epub 2016 Jan 29.

PMID:
26829386
8.

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.

Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, Shimazu N, Yamaguchi S, Kanno K, Ogawa Y.

PLoS One. 2016 Mar 15;11(3):e0151511. doi: 10.1371/journal.pone.0151511. eCollection 2016.

9.

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, Koepsell H, Thomson SC, Rieg T.

Am J Physiol Renal Physiol. 2014 Jan;306(2):F194-204. doi: 10.1152/ajprenal.00520.2013. Epub 2013 Nov 13.

10.

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.

Yokono M, Takasu T, Hayashizaki Y, Mitsuoka K, Kihara R, Muramatsu Y, Miyoshi S, Tahara A, Kurosaki E, Li Q, Tomiyama H, Sasamata M, Shibasaki M, Uchiyama Y.

Eur J Pharmacol. 2014 Mar 15;727:66-74. doi: 10.1016/j.ejphar.2014.01.040. Epub 2014 Jan 30.

PMID:
24486393
11.

TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.

Yamamoto K, Uchida S, Kitano K, Fukuhara N, Okumura-Kitajima L, Gunji E, Kozakai A, Tomoike H, Kojima N, Asami J, Toyoda H, Arai M, Takahashi T, Takahashi K.

Br J Pharmacol. 2011 Sep;164(1):181-91. doi: 10.1111/j.1476-5381.2011.01340.x.

12.

Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.

Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S.

Horm Metab Res. 2015 Aug;47(9):686-92. doi: 10.1055/s-0034-1395609. Epub 2015 Jan 22.

PMID:
25611208
13.

Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.

Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T, Takeda M, Yata T, Kawai M, Fukuzawa T, Kobayashi T, Sato T, Kawabe Y, Ikeda S.

J Pharmacol Exp Ther. 2012 Jun;341(3):692-701. doi: 10.1124/jpet.112.191593. Epub 2012 Mar 12.

14.

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W.

Diabetes Technol Ther. 2011 Dec;13(12):1219-27. doi: 10.1089/dia.2011.0012. Epub 2011 Aug 19.

PMID:
21854192
15.

Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.

Luippold G, Klein T, Mark M, Grempler R.

Diabetes Obes Metab. 2012 Jul;14(7):601-7. doi: 10.1111/j.1463-1326.2012.01569.x. Epub 2012 Feb 23.

PMID:
22268612
16.

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

Kurosaki E, Ogasawara H.

Pharmacol Ther. 2013 Jul;139(1):51-9. doi: 10.1016/j.pharmthera.2013.04.003. Epub 2013 Apr 4. Review.

PMID:
23563279
17.

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.

Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, Ishikawa-Takemura Y, Kusama H, Isaji M.

Eur J Pharmacol. 2009 May 1;609(1-3):148-54. doi: 10.1016/j.ejphar.2009.03.007. Epub 2009 Mar 10.

PMID:
19281809
18.

Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.

Kadokura T, Zhang W, Krauwinkel W, Leeflang S, Keirns J, Taniuchi Y, Nakajo I, Smulders R.

Clin Pharmacokinet. 2014 Nov;53(11):975-88. doi: 10.1007/s40262-014-0180-z. Review.

PMID:
25316572
19.

T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats.

Adachi T, Yasuda K, Okamoto Y, Shihara N, Oku A, Ueta K, Kitamura K, Saito A, Iwakura I, Yamada Y, Yano H, Seino Y, Tsuda K.

Metabolism. 2000 Aug;49(8):990-5.

PMID:
10954015
20.

Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.

Gangadharan Komala M, Gross S, Mudaliar H, Huang C, Pegg K, Mather A, Shen S, Pollock CA, Panchapakesan U.

PLoS One. 2014 Nov 4;9(11):e108994. doi: 10.1371/journal.pone.0108994. eCollection 2014.

Items per page

Supplemental Content

Write to the Help Desk